Category: Patent Litigation

By James DeGiulio — Takeda Completes Settlements with 11 Generics, Finally Ending Actos Patent Dispute Takeda has completed settlements with all defendants in the patent litigation brought against several generic companies in response to their ANDAs for the diabetes drug Actos.  Takeda has filed a number of infringement suits in the Southern District of New…

By James DeGiulio — Roche Dodges Cobalt Invalidity Contention in Boniva Patent Suit In a decision handed down earlier this week, the U.S. District Court for the District of New Jersey rejected Cobalt Pharmaceuticals' attempt to invalidate Roche's patent covering Boniva for incorrect inventorship.  After Apotex and Cobalt filed Abbreviated New Drug Applications (ANDAs) for…

By James DeGiulio — Former Professor Fails to Dismiss St. John's Patent Research Suit Sanford Bolton, a former professor at St. John's University, and graduate student Spiridon Spireas have failed to dismiss a fraud and breach of contract suit by St. John's, accusing them of secretly patenting research done at the university and collecting more…

By James DeGiulio — Amgen's Bid for Summary Judgment in Neupogen Suit with Teva Falls Short Amgen has been unsuccessful in its attempt to secure partial summary judgment of infringement against Teva with regard to Amgen's patents covering the blood drug Neupogen.  In December 2009, Teva brought a declaratory judgment action in the U.S. District…

By James DeGiulio — Otsuka Abilify Patent Found Valid and Enforceable Otsuka Pharmaceutical Co. won a key court ruling that upheld its patent covering Abilify, thereby preventing Teva, Apotex, and Sandoz from releasing generic versions of the drug until April 2015. In 2007, Otsuka sued several defendants, including Teva, Apotex, and Sandoz, after the defendants…

By James DeGiulio — Roche Succeeds in Blocking Release of Cobalt's Generic Boniva Hoffman-La Roche successfully secured a preliminary injunction against Cobalt Pharmaceuticals in the patent suit over the bone-loss drug Boniva, thus preventing Cobalt from launching a generic version of the drug. Apotex and Cobalt filed Abbreviated New Drug Applications (ANDAs) for generic ibandronate,…

By James DeGiulio — Sanofi and BMS Awarded $442M in Plavix Patent Suit Apotex has been ordered to pay $442.2 million in damages to sanofi-aventis and Bristol-Myers Squibb Co. for infringing their patent covering the blood thinner Plavix. Sanofi sued Apotex in the U.S. District Court for the Southern District of New York in 2002,…

By James DeGiulio — Novo Fails to Dismiss Suit over Validity of Prandin Patent The five year dispute over the validity of the patent covering the diabetes drug Prandin continues, as Novo Nordisk's attempt to dismiss the case with Sun Pharmaceutical Industries and Caraco Pharmaceutical Laboratories was recently denied. Novo originally filed suit against Caraco…

By James DeGiulio — Impax Settles Amrix Patent Suit with Cephalon Impax and Cephalon have reached an agreement to settle the suit over Impax's generic version of Cephalon's muscle relaxant drug Amrix. Impax filed an Abbreviated New Drug Application (ANDA) for its generic version of Amrix in September 2008, and Cephalon brought suit against Impax…

By James DeGiulio — Roche Boniva Patent Dispute with Apotex, Cobalt Goes to Jury Cross-motions for summary judgment by Roche and defendants Apotex and Cobalt were denied in Roche's infringement suit regarding generic versions of Boniva.  The case will now go before a jury to resolve questions of fact. Apotex and Cobalt filed ANDAs for…